{"id":341472,"date":"2026-11-06T10:49:03","date_gmt":"2026-11-06T05:19:03","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=341472"},"modified":"2026-11-06T10:49:03","modified_gmt":"2026-11-06T05:19:03","slug":"branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/","title":{"rendered":"3 Branded Consumer Products Company, Diagnostics Chain and Luxury Hotels Operator Stocks With a Strong Future Roadmap: Godfrey Phillips India, Dr. Lal PathLabs and Indian Hotels Company"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Godfrey Phillips India, Dr. Lal PathLabs and Indian Hotels Company: ROE of 16.0% to 24.6% and FY22 to FY26 revenue CAGR of 7.6% to 32.7%. Prices as of 5 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three consumer brand, diagnostics and hotel stocks to watch are Godfrey Phillips India, Dr. Lal PathLabs and Indian Hotels Company. Their return on equity ranges from 16.0% to 24.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 32.7%. Godfrey Phillips India has the highest return on equity at 24.6%, while Indian Hotels Company has the fastest revenue growth at 32.7% a year. Prices are based on the 5 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Consumer brand, diagnostics and hotel stocks offer a focused view of a sector where demand keeps widening. Godfrey Phillips India, Dr. Lal PathLabs and Indian Hotels Company cover a branded consumer products company, a diagnostics chain and a luxury hotels operator.<\/p>\n<p>This list covers three consumer brand, diagnostics and hotel stocks with complete current figures: Godfrey Phillips India, Dr. Lal PathLabs and Indian Hotels Company. Every figure comes from the latest reported financials and the 5 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#What_Are_Consumer_Brand_Diagnostics_and_Hotel_Stocks\" title=\"What Are Consumer Brand, Diagnostics and Hotel Stocks?\">What Are Consumer Brand, Diagnostics and Hotel Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#Consumer_Brand_Diagnostics_and_Hotel_Stocks_at_a_Glance\" title=\"Consumer Brand, Diagnostics and Hotel Stocks at a Glance\">Consumer Brand, Diagnostics and Hotel Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#Why_Do_Consumer_Brand_Diagnostics_and_Hotel_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Consumer Brand, Diagnostics and Hotel Stocks Have a Strong Roadmap in India?\">Why Do Consumer Brand, Diagnostics and Hotel Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#Why_Godfrey_Phillips_India_Features_Among_These_Consumer_Brand_Diagnostics_and_Hotel_Stocks\" title=\"Why Godfrey Phillips India Features Among These Consumer Brand, Diagnostics and Hotel Stocks\">Why Godfrey Phillips India Features Among These Consumer Brand, Diagnostics and Hotel Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#Why_Dr_Lal_PathLabs_Features_Among_These_Consumer_Brand_Diagnostics_and_Hotel_Stocks\" title=\"Why Dr. Lal PathLabs Features Among These Consumer Brand, Diagnostics and Hotel Stocks\">Why Dr. Lal PathLabs Features Among These Consumer Brand, Diagnostics and Hotel Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#Why_Indian_Hotels_Company_Features_Among_These_Consumer_Brand_Diagnostics_and_Hotel_Stocks\" title=\"Why Indian Hotels Company Features Among These Consumer Brand, Diagnostics and Hotel Stocks\">Why Indian Hotels Company Features Among These Consumer Brand, Diagnostics and Hotel Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#Godfrey_Phillips_India_vs_Dr_Lal_PathLabs_vs_Indian_Hotels_Company_on_Key_Financials\" title=\"Godfrey Phillips India vs Dr. Lal PathLabs vs Indian Hotels Company on Key Financials\">Godfrey Phillips India vs Dr. Lal PathLabs vs Indian Hotels Company on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#Key_Risks_to_Check_Before_Investing_in_Consumer_Brand_Diagnostics_and_Hotel_Stocks\" title=\"Key Risks to Check Before Investing in Consumer Brand, Diagnostics and Hotel Stocks\">Key Risks to Check Before Investing in Consumer Brand, Diagnostics and Hotel Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#Final_Thoughts_on_Consumer_Brand_Diagnostics_and_Hotel_Stocks\" title=\"Final Thoughts on Consumer Brand, Diagnostics and Hotel Stocks\">Final Thoughts on Consumer Brand, Diagnostics and Hotel Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#What_are_consumer_brand_diagnostics_and_hotel_stocks\" title=\"What are consumer brand, diagnostics and hotel stocks?\">What are consumer brand, diagnostics and hotel stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#Which_consumer_brand_diagnostics_and_hotel_stocks_are_covered_in_this_list\" title=\"Which consumer brand, diagnostics and hotel stocks are covered in this list?\">Which consumer brand, diagnostics and hotel stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#Why_do_consumer_brand_diagnostics_and_hotel_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do consumer brand, diagnostics and hotel stocks have a strong future roadmap in India?\">Why do consumer brand, diagnostics and hotel stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#How_has_Godfrey_Phillips_India_performed_financially\" title=\"How has Godfrey Phillips India performed financially?\">How has Godfrey Phillips India performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#How_has_Dr_Lal_PathLabs_performed_financially\" title=\"How has Dr. Lal PathLabs performed financially?\">How has Dr. Lal PathLabs performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#How_has_Indian_Hotels_Company_performed_financially\" title=\"How has Indian Hotels Company performed financially?\">How has Indian Hotels Company performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#What_risks_should_investors_check_before_buying_consumer_brand_diagnostics_and_hotel_stocks\" title=\"What risks should investors check before buying consumer brand, diagnostics and hotel stocks?\">What risks should investors check before buying consumer brand, diagnostics and hotel stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator-stocks-roadmap-hillcrest-list\/#Is_this_list_of_consumer_brand_diagnostics_and_hotel_stocks_investment_advice\" title=\"Is this list of consumer brand, diagnostics and hotel stocks investment advice?\">Is this list of consumer brand, diagnostics and hotel stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Consumer_Brand_Diagnostics_and_Hotel_Stocks\"><\/span><strong>What Are Consumer Brand, Diagnostics and Hotel Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Consumer brand, diagnostics and hotel stocks are listed companies that make and sell branded consumer products, run a network of pathology labs and collection centres, and operate luxury and premium hotels and resorts. Their earnings depend on consumer spending, test volumes and room demand.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Consumer_Brand_Diagnostics_and_Hotel_Stocks_at_a_Glance\"><\/span><strong>Consumer Brand, Diagnostics and Hotel Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/godfryphlp\/godfrey-phillips-india-ltd-share-price-today\">Godfrey Phillips India<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,794<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">28,186<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.04<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/lalpathlab\/dr-lal-pathlabs-ltd-share-price-today\">Dr. Lal PathLabs<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,966.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">30,949<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">56.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.08<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/indhotel\/the-indian-hotels-company-ltd-share-price-today\">Indian Hotels Company<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">875<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">108,181<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">46.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">37.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.22<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Dr. Lal PathLabs trades at a P\/E below the industry P\/E, while Godfrey Phillips India and Indian Hotels Company trade above it, which reflects the growth the market already expects. Readers comparing consumer brand, diagnostics and hotel stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in consumer brand, diagnostics and hotel stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Consumer_Brand_Diagnostics_and_Hotel_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Consumer Brand, Diagnostics and Hotel Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Consumer brand, diagnostics and hotel stocks have a strong roadmap in India because rising incomes, growing health awareness and strong demand for premium travel keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Consumer brands.<\/strong> Established brands reach more outlets.<\/li>\n<li><strong>Diagnostics.<\/strong> Regular health tests become common.<\/li>\n<li><strong>Hotels.<\/strong> Premium travel fills luxury rooms.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Godfrey_Phillips_India_Features_Among_These_Consumer_Brand_Diagnostics_and_Hotel_Stocks\"><\/span><strong>Why Godfrey Phillips India Features Among These Consumer Brand, Diagnostics and Hotel Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the consumer brand, diagnostics and hotel stocks on this list, Godfrey Phillips India makes cigarettes and tobacco products under brands such as Four Square and Cavanders, and also sells confectionery and retails through its subsidiaries.<\/p>\n<p>Revenue rose from Rs 2,802 crore in FY22 to Rs 6,596 crore in FY26, a compound annual growth rate of 23.9%. Net profit grew from Rs 438 crore in FY22 to Rs 1,525 crore in FY26, which works out to a compound annual growth rate of 36.6%.<\/p>\n<p>The company has a return on equity of 24.6%, a debt to equity ratio of 0.04 and a market capitalisation of Rs 28,186 crore. The stock trades at a P\/E of 20.6, above the industry P\/E of 18.6.<\/p>\n<p><strong>Roadmap:<\/strong> The company has strong brands in the premium and mid-price segments and has widened its product range and distribution. Export sales and investments in retail and other businesses broaden its income sources.<\/p>\n<p><strong>What to watch:<\/strong> Monitor volume trends and policy changes on tobacco taxation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Dr_Lal_PathLabs_Features_Among_These_Consumer_Brand_Diagnostics_and_Hotel_Stocks\"><\/span><strong>Why Dr. Lal PathLabs Features Among These Consumer Brand, Diagnostics and Hotel Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the packaged brand, pathology and hospitality shares on this list, Dr. Lal PathLabs is one of India&#8217;s best-known diagnostics companies, operating a national reference laboratory with a hub-and-spoke network of labs, patient service centres and collection points.<\/p>\n<p>The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P\/E of 56.6, below the industry P\/E of 59.6.<\/p>\n<p>Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore.<\/p>\n<p><strong>Roadmap:<\/strong> Its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.<\/p>\n<p><strong>What to watch:<\/strong> Follow test volumes per patient and the balance between routine and specialised tests.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Indian_Hotels_Company_Features_Among_These_Consumer_Brand_Diagnostics_and_Hotel_Stocks\"><\/span><strong>Why Indian Hotels Company Features Among These Consumer Brand, Diagnostics and Hotel Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Indian Hotels Company is India&#8217;s largest hospitality company and part of the Tata Group, operating luxury, upscale and mid-market hotels and resorts under Taj, SeleQtions, Vivanta and Ginger, along with a food, dining and residences business.<\/p>\n<p>Revenue rose from Rs 3,211 crore in FY22 to Rs 9,971 crore in FY26, a compound annual growth rate of 32.7%. Net profit grew from Rs 971 crore in FY23 to Rs 2,195 crore in FY26, which works out to a compound annual growth rate of 31.2%.<\/p>\n<p>In the June 2026 quarter, revenue grew 15.1% year on year to Rs 2,419 crore, while net profit rose 22.4% to Rs 391 crore. The company has a return on equity of 16.0%, a debt to equity ratio of 0.22 and a market capitalisation of Rs 108,181 crore. The stock trades at a P\/E of 46.9, above the industry P\/E of 37.9.<\/p>\n<p><strong>Roadmap:<\/strong> The company is growing mainly through management contracts and new signings, which add rooms without heavy capital outlay. Its strong brands, a pipeline of new hotels and rising travel and event demand support growth in occupancy and room rates.<\/p>\n<p><strong>What to watch:<\/strong> Track new room signings and openings and the pace of growth in its newer brands.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Godfrey_Phillips_India_vs_Dr_Lal_PathLabs_vs_Indian_Hotels_Company_on_Key_Financials\"><\/span><strong>Godfrey Phillips India vs Dr. Lal PathLabs vs Indian Hotels Company on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three consumer brand, diagnostics and hotel stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Godfrey Phillips India<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,802<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6,596<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,525<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Dr. Lal PathLabs<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,140<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,864<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">510<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Indian Hotels Company<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,211<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,971<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">32.7%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,195<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.0%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Godfrey Phillips India posts the highest return on equity in this group at 24.6%. Indian Hotels Company combines the largest FY26 revenue at Rs 9,971 crore with the fastest revenue growth, a 32.7% compound annual rate. A useful habit with consumer brand, diagnostics and hotel stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Consumer_Brand_Diagnostics_and_Hotel_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Consumer Brand, Diagnostics and Hotel Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these consumer brand, diagnostics and hotel stocks, the main points are: Long-term packaged brand, pathology and hospitality shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Consumer spending.<\/strong> Sales follow festivals, incomes and consumer mood.<\/li>\n<li><strong>Test volumes.<\/strong> Footfall and test mix can vary with seasons.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter consumer brand, diagnostics and hotel stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Consumer_Brand_Diagnostics_and_Hotel_Stocks\"><\/span><strong>Final Thoughts on Consumer Brand, Diagnostics and Hotel Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Consumer brand, diagnostics and hotel stocks reward patient research into demand, execution and financial strength. Godfrey Phillips India, Dr. Lal PathLabs and Indian Hotels Company each have a clear plan to grow. Based on the 5 November 2026 close, Godfrey Phillips India trades at Rs 1,794, Dr. Lal PathLabs at Rs 1,966.8 and Indian Hotels Company at Rs 875. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these consumer brand, diagnostics and hotel stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track consumer brand, diagnostics and hotel stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_consumer_brand_diagnostics_and_hotel_stocks\"><\/span><strong>What are consumer brand, diagnostics and hotel stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Consumer brand, diagnostics and hotel stocks are listed companies that make and sell branded consumer products, run a network of pathology labs and collection centres, and operate luxury and premium hotels and resorts. Their earnings depend on consumer spending, test volumes and room demand. This list looks at three of them, Godfrey Phillips India, Dr. Lal PathLabs and Indian Hotels Company, using reported FY22 to FY26 financials and the 5 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_consumer_brand_diagnostics_and_hotel_stocks_are_covered_in_this_list\"><\/span><strong>Which consumer brand, diagnostics and hotel stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Godfrey Phillips India, Dr. Lal PathLabs and Indian Hotels Company. Based on the 5 November 2026 close, Godfrey Phillips India traded at Rs 1,794, Dr. Lal PathLabs at Rs 1,966.8 and Indian Hotels Company at Rs 875. Their return on equity ranges from 16.0% to 24.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 32.7%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_consumer_brand_diagnostics_and_hotel_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do consumer brand, diagnostics and hotel stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Consumer brand, diagnostics and hotel stocks have a strong roadmap in India because rising incomes, growing health awareness and strong demand for premium travel keep widening the market for these companies. The main drivers are as follows. Consumer brands. Established brands reach more outlets. Diagnostics. Regular health tests become common. Hotels. Premium travel fills luxury rooms. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Godfrey_Phillips_India_performed_financially\"><\/span><strong>How has Godfrey Phillips India performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 2,802 crore in FY22 to Rs 6,596 crore in FY26, a compound annual growth rate of 23.9%. Net profit grew from Rs 438 crore in FY22 to Rs 1,525 crore in FY26, which works out to a compound annual growth rate of 36.6%. The company has a return on equity of 24.6%, a debt to equity ratio of 0.04 and a market capitalisation of Rs 28,186 crore. The stock trades at a P\/E of 20.6, above the industry P\/E of 18.6. Looking ahead, the company has strong brands in the premium and mid-price segments and has widened its product range and distribution. Export sales and investments in retail and other businesses broaden its income sources.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Dr_Lal_PathLabs_performed_financially\"><\/span><strong>How has Dr. Lal PathLabs performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P\/E of 56.6, below the industry P\/E of 59.6. Looking ahead, its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Indian_Hotels_Company_performed_financially\"><\/span><strong>How has Indian Hotels Company performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 3,211 crore in FY22 to Rs 9,971 crore in FY26, a compound annual growth rate of 32.7%. Net profit grew from Rs 971 crore in FY23 to Rs 2,195 crore in FY26, which works out to a compound annual growth rate of 31.2%. In the June 2026 quarter, revenue grew 15.1% year on year to Rs 2,419 crore, while net profit rose 22.4% to Rs 391 crore. The company has a return on equity of 16.0%, a debt to equity ratio of 0.22 and a market capitalisation of Rs 108,181 crore. The stock trades at a P\/E of 46.9, above the industry P\/E of 37.9. Looking ahead, the company is growing mainly through management contracts and new signings, which add rooms without heavy capital outlay. Its strong brands, a pipeline of new hotels and rising travel and event demand support growth in occupancy and room rates.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_consumer_brand_diagnostics_and_hotel_stocks\"><\/span><strong>What risks should investors check before buying consumer brand, diagnostics and hotel stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying consumer brand, diagnostics and hotel stocks. Consumer spending. Sales follow festivals, incomes and consumer mood. Test volumes. Footfall and test mix can vary with seasons. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_consumer_brand_diagnostics_and_hotel_stocks_investment_advice\"><\/span><strong>Is this list of consumer brand, diagnostics and hotel stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 5 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are consumer brand, diagnostics and hotel stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Consumer brand, diagnostics and hotel stocks are listed companies that make and sell branded consumer products, run a network of pathology labs and collection centres, and operate luxury and premium hotels and resorts. Their earnings depend on consumer spending, test volumes and room demand. This list looks at three of them, Godfrey Phillips India, Dr. Lal PathLabs and Indian Hotels Company, using reported FY22 to FY26 financials and the 5 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which consumer brand, diagnostics and hotel stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Godfrey Phillips India, Dr. Lal PathLabs and Indian Hotels Company. Based on the 5 November 2026 close, Godfrey Phillips India traded at Rs 1,794, Dr. Lal PathLabs at Rs 1,966.8 and Indian Hotels Company at Rs 875. Their return on equity ranges from 16.0% to 24.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 32.7%.\"}},{\"@type\":\"Question\",\"name\":\"Why do consumer brand, diagnostics and hotel stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Consumer brand, diagnostics and hotel stocks have a strong roadmap in India because rising incomes, growing health awareness and strong demand for premium travel keep widening the market for these companies. The main drivers are as follows. Consumer brands. Established brands reach more outlets. Diagnostics. Regular health tests become common. Hotels. Premium travel fills luxury rooms. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Godfrey Phillips India performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 2,802 crore in FY22 to Rs 6,596 crore in FY26, a compound annual growth rate of 23.9%. Net profit grew from Rs 438 crore in FY22 to Rs 1,525 crore in FY26, which works out to a compound annual growth rate of 36.6%. The company has a return on equity of 24.6%, a debt to equity ratio of 0.04 and a market capitalisation of Rs 28,186 crore. The stock trades at a P\/E of 20.6, above the industry P\/E of 18.6. Looking ahead, the company has strong brands in the premium and mid-price segments and has widened its product range and distribution. Export sales and investments in retail and other businesses broaden its income sources.\"}},{\"@type\":\"Question\",\"name\":\"How has Dr. Lal PathLabs performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P\/E of 56.6, below the industry P\/E of 59.6. Looking ahead, its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.\"}},{\"@type\":\"Question\",\"name\":\"How has Indian Hotels Company performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 3,211 crore in FY22 to Rs 9,971 crore in FY26, a compound annual growth rate of 32.7%. Net profit grew from Rs 971 crore in FY23 to Rs 2,195 crore in FY26, which works out to a compound annual growth rate of 31.2%. In the June 2026 quarter, revenue grew 15.1% year on year to Rs 2,419 crore, while net profit rose 22.4% to Rs 391 crore. The company has a return on equity of 16.0%, a debt to equity ratio of 0.22 and a market capitalisation of Rs 108,181 crore. The stock trades at a P\/E of 46.9, above the industry P\/E of 37.9. Looking ahead, the company is growing mainly through management contracts and new signings, which add rooms without heavy capital outlay. Its strong brands, a pipeline of new hotels and rising travel and event demand support growth in occupancy and room rates.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying consumer brand, diagnostics and hotel stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying consumer brand, diagnostics and hotel stocks. Consumer spending. Sales follow festivals, incomes and consumer mood. Test volumes. Footfall and test mix can vary with seasons. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of consumer brand, diagnostics and hotel stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 5 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Consumer Brand, Diagnostics and Hotel Stocks with a strong future roadmap: Godfrey Phillips India, Dr. Lal PathLabs and Indian Hotels Company. Compare price, valuation, return on equity and revenue growth as of 5 November 2026.<\/p>\n","protected":false},"author":36,"featured_media":341471,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,21015,11547,21012,8584,9557,8493,21016,21013,21014],"class_list":["post-341472","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-branded-products","tag-consumer-brand","tag-diagnostics-and-hotel-stocks","tag-dr-lal-pathlabs-2","tag-godfrey-phillips-india","tag-indian-hotels-company","tag-lab-testing-and-luxury-stay-stocks","tag-packaged-brand","tag-pathology-and-hospitality-shares"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["341471"],"rank_math_title":["Consumer Brand, Diagnostics and Hotel Stocks"],"rank_math_description":["Compare 3 consumer brand, diagnostics and hotel stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 5 Nov 2026."],"rank_math_focus_keyword":["consumer brand, diagnostics and hotel stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-branded-consumer-products-company-diagnostics-chain-and-luxury-hotels-operator.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/341472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=341472"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/341472\/revisions"}],"predecessor-version":[{"id":341473,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/341472\/revisions\/341473"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/341471"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=341472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=341472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=341472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}